Abstract
Venous thromboembolism is a frequent and serious vascular disease that can lead to serious complications. Rational and accurate establishment of the diagnosis enables early treatment that reduces the occurrence and severity of acute and chronic complications.
Conservative treatment of this disease has reached a turning point with the introduction of novel direct oral anticoagulants. According to present guidelines, standard treatment with low molecular heparines such as Fondaparinux and vitamine K antagonists still remain a clinically effective therapeutic option not only in the acute phase, but also in the secondary and long term prophylaxis of the disease.
Direct oral anticoagulants represent an important alternative to conventional anticoagulants and appeared in new ESC recommendations of pulmonary embolism.